Argenx acquires Forte for $2.2B for ph.2-stage vitiligo drug - Fierce Biotech

What the report says

FierceBiotech reported that Argenx plans to acquire Forte Biosciences in a deal valued at $2.2 billion, giving the Belgian-Dutch biotech access to Forte’s phase 2-stage drug candidate. The report identifies the asset as being developed for vitiligo and celiac disease, with the headline emphasizing its potential role in vitiligo.

The core development is a pipeline-driven takeover: Argenx, already known in biotechnology for immune-focused drug development, is paying to bring Forte and its mid-stage clinical program in-house. The article text available publicly is limited, so details such as the transaction structure, expected closing date, regulatory conditions, trial data, or Argenx’s commercial plans were not available from the supplied source.

The deal matters because phase 2 assets can become strategically important if they show enough evidence to justify later-stage trials, particularly in immune-mediated conditions where companies are seeking differentiated therapies. Vitiligo is a chronic condition involving loss of skin pigment, while celiac disease is an immune reaction to gluten; both are areas where treatment options and patient needs continue to shape drug-development interest.

Based on the FierceBiotech report, the acquisition reflects Argenx’s willingness to spend significantly for a clinical-stage program before pivotal testing. Further assessment will depend on information not provided in the snippet, including the drug’s mechanism, existing clinical results, safety profile, and how Argenx intends to prioritize the vitiligo and celiac disease opportunities after absorbing Forte.